Yahoo Finance report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
Why COSM Stock surged +10.96% Today — RQD Quant Desk Flash
Cosmos Health Inc. (COSM) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Cosmos Health Inc. (NASDAQ: COSM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $0.31 (+10.96% 1D, market cap $27.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, COSM ranks #885 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COSM compare to ESYN and ZSTK in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), COSM carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 12.1%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and ZSTK (ZeroStack Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $63.9M). Among the 5-stock peer group, COSM leads on earnings multiple (N/A) while COSM leads on capital efficiency (-35.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COSM?
▼
Per COSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001474167), Cosmos Health Inc. generated $65.3M in revenue (+19.9% YoY), -$19.1M in net income, and -$8.5M in free cash flow against $65.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 46.4 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a COSM Turnaround Squeeze
While COSM currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.30) and Max Pain ($0.33) forces dealer call-delta covering toward $1.00.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why COSM Stock surged +10.96% Today — RQD Quant Desk Flash
Cosmos Health Inc. (COSM) surged +10.96% to $0.31, trading at 19% of its 52-week range ($0.16 – $0.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 19% of its 52-week range ($0.16 – $0.95) with RSI-14 at 46.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 12.1% gross margin and $0 annual free cash flow.
Moomoo report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
* Active subscriptions up 92%: 12,050 active U. direct-to-consumer subscription business.
* Rating and price target: Outperform rating with a $1.40 price target * Implied upside: approximately 493% above the $0.
The business is now live across the region, and sales are already underway.Expansion OverviewCustomers across Australia, New Zealand and the broader Oceania region can now purchase Cosmos Health products directly through
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COSM)
- ✓Walkthrough of COSM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
COSM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +19.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on COSM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for COSM. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COSM)
1. Head-to-Head Health Care Peer Comparison (COSM vs. ESYN, ZSTK, MEDS, HKPD)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cosmos Health Inc. (COSM) ranks #885 by composite RQD confidence (29/100, grade E) and #811 by equity capitalization ($27.9M). Within this direct 5-issuer industry benchmark cohort, COSM leads on earnings valuation at N/A trailing P/E, while COSM leads on capital efficiency and profitability with -35.0% ROIC and 12.1% gross margin. HKPD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with COSM at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COSM
ACTIVE
Cosmos Health Inc. | E | 29/100 | — | 12.1% | -35.0% | +10.96% | $27.9M | Benchmark Subject |
| ESYN EnerSyn Global Inc. | D- | 40/100 | — | 53.0% | -35.0% | -4.37% | $54.4M | /esyn-vs-cosm → |
| ZSTK ZeroStack Corp. | E | 25/100 | — | 4.6% | -35.0% | -5.12% | $63.9M | /zstk-vs-cosm → |
| MEDS DataMeds AI Inc. | E | 28/100 | — | -27.5% | -35.0% | -5.42% | $9.8M | /meds-vs-cosm → |
| HKPD Cellyan Biotechnology Co. Ltd (Class A) | D | 46/100 | — | — | — | -9.59% | $5.4M | /hkpd-vs-cosm → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001474167In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cosmos Health Inc. (COSM) reported GAAP revenue of $65.3M (+19.9% vs. FY2024 revenue of $54.4M , and +22.3% cumulative change since FY2023) , GAAP net income of -$19.1M, operating cash flow of -$8.4M, and free cash flow of -$8.5M (-4.5% YoY). On the balance sheet, COSM closed FY2025 with $65.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $65.3M | -$19.1M | -$8.4M | -$8.5M | $65.5M | — |
| FY2024 (FY) | 2024-12-31 | $54.4M | -$16.2M | -$7.7M | -$8.1M | $54.3M | — |
| FY2023 (FY) | 2023-12-31 | $53.4M | -$18.5M | -$15.6M | -$15.6M | — | — |
3. COSM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Cosmos Health Inc. (NASDAQ: COSM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $0.31 (+10.96% 1D, market cap $27.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, COSM ranks #885 in composite RQD confidence.
How does COSM compare to ESYN and ZSTK in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), COSM carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of 12.1%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and ZSTK (ZeroStack Corp.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $63.9M). Among the 5-stock peer group, COSM leads on earnings multiple (N/A) while COSM leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COSM?
Per COSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001474167), Cosmos Health Inc. generated $65.3M in revenue (+19.9% YoY), -$19.1M in net income, and -$8.5M in free cash flow against $65.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COSM trading relative to its 50-day, 200-day, and 52-week technical levels?
COSM last traded at $0.31 (+10.96% on volume of 2,110,063 shares), positioning the stock +3.33% above its 50-day simple moving average ($0.30) and 0.00% above its 200-day simple moving average ($0.31). Across its 52-week range of $0.16 to $0.95, COSM sits at the 19.0% percentile with a 14-day RSI of 46.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).
COSM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is COSM stock moving today?
Why COSM Stock surged +10.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
COSM — Cosmos Health Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, COSM scores 29 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 4 / 20 (ROIC -35%; FCF yield 0%). This is the weakest economic signal: the company is not currently converting capital into positive returns or free cash flow, per the source.
- Whale 13F Flow: 13 / 20 (institutional accumulation and options positioning). This is the strongest pillar, indicating comparatively more institutional and options-based interest than the other pillars.
- Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). The low score signals weak insider-side conviction in the source's measurement.
- Macro Regime Fit: 7 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive or low-volatility characteristic.
- Forensic Balance Sheet: 2 / 20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). This is the most alarming pillar; the Altman Z-Score sits in a range typically associated with distress, and the Piotroski F-Score of 3/9 indicates weak fundamental quality.
For a prospective investor evaluating the stock today, the upside case rests almost entirely on the institutional flow pillar and on the recent revenue catalysts discussed below. The valuation tradeoff is stark: with a market capitalization of $27.9M, a 52-week range of $0.16 - $0.95, and a stock price of 0.28, the price has moved sharply over the period, while the underlying forensic and cash-generation metrics remain weak. Any valuation argument must be weighed against a negative ROIC and zero FCF yield. The 2nd-order implication is that revenue growth alone has not translated into cash returns per the source data, so investors would need to see a path to cash conversion before the rating would plausibly improve.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $65.3M | $-16.7M | $-19.1M | N/A | $-8.5M | $0.7M | N/A |
| FY 2024 | $54.4M | $-15.5M | $-16.2M | N/A | $-8.1M | $0.3M | N/A |
| FY 2023 | $53.4M | $-21.8M | $-18.5M | N/A | $-15.6M | N/A | N/A |
Per the SEC financials, revenue rose from $53.4M (FY 2023) to $54.4M (FY 2024) to $65.3M (FY 2025), while operating losses and net losses persisted in every reported period. Market data reports a gross margin of 12.1%, an operating margin of -25.6%, and a net margin of -29.3%, with ROIC at -35%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both per the forensic balance sheet pillar. Debt-to-equity is 0.5 per the same pillar. Reported cash is small at $0.7M in FY 2025, and free cash flow was negative in each reported year.
Recent Catalysts & News Wire Analysis
- Revenue update (GREEN, CATALYST): Headlines from Yahoo Finance and Stock Titan report record preliminary nine-month revenue of $54.3 Million, up 19% year over year, and record Q3 revenue of $17.4 Million, and state that the company reaffirmed a 2026 revenue outlook of over $90 Million.
- Analyst initiation (GREEN, CATALYST): Investing.com reports that Noble Capital initiated coverage with an outperform rating.
- Market and options coverage (YELLOW, MARKET WIRE): Moomoo options-chain coverage, Simply Wall St forecast coverage, and TradingView estimates coverage were flagged as market-wire items without a directional fundamental claim.
- Risk watch: Headline revenue growth has not, per the source data, been accompanied by positive operating income, net income, or free cash flow. The 2026 outlook is a company-reported expectation and is not independently verified in the source.
- Proprietary signals: None are listed in the Butterfly Supply-Chain Graph.
Open Questions
- What are the company's specific products, customers, and revenue drivers behind the reported revenue growth?
- What is the path from negative operating and free cash flow to positive cash generation?
- What are the debt levels and terms, given that debt is N/A in the reported financials while the RQD cites a debt-to-equity of 0.5?
- What is the basis for the 2026 revenue outlook of over $90 Million, and what assumptions underlie it?
- What is the analyst consensus, price target, and holder composition that would contextualize the Noble Capital outperform initiation?
COSM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cosmos Health Inc. (COSM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Cosmos Health Inc. (COSM) market action, institutional positioning, and fundamental catalysts.
* Active subscriptions up 92%: 12,050 active U. direct-to-consumer subscription business.
COSM Bull vs. Bear Conversation Board — What's Your Call at $0.31?
🔥 Official Bull vs. Bear Debate: Is COSM (E • RQD 29/100) a Buy at $0.28?
Welcome to the COSM (Cosmos Health Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Other Pharmaceuticals. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on COSM — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on COSM, but look at what you are paying: current EV/EBITDA multiples with 12.1% gross margins. Unless Cosmos Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
COSM cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on COSM, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $0.28 (52-wk range $0.16 - $0.95), any beat on forward guidance forces shorts and underweight funds to chase.